Alk-Abello As B Shs New (AKBLF) Q4 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Alk-abello A/s Class B.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.908 -- 00:00:06.935 Hello, and welcome to the presentation of ALK's Q4 and full year 2025 results. 00:00:06.935 -- 00:00:11.941 My name is Per Plotnikoff. I'm head of investor relations, and thank you all for joining. 00:00:11.941 -- 00:00:16.887 On slide two, I will present the speakers and agenda for this call. 00:00:16.887 -- 00:00:22.542 And with me today are CEO Peter Halling and CFO Claus Steensen Sølje. 00:00:22.542 -- 00:00:27.147 Peter and Claus will walk you through the Q4 and full year highlights, market and product 00:00:27.147 -- 00:00:30.791 trends, as well as the full year financial performance. 00:00:30.791 -- 00:00:35.777 Then we will provide an update on the strategic progress and priorities before presenting 00:00:35.777 -- 00:00:38.558 our outlook for 2026. 00:00:38.640 -- 00:00:43.686 As usual, we will end with a Q&A session. And to get us started, I'll hand 00:00:43.686 -- 00:00:48.211 you over to Peter and slide number three. Please go ahead, Peter. 00:00:48.211 -- 00:00:52.850 Thank you, Peter. And thank you all for joining the call. 00:00:52.850 -- 00:00:58.277 We delivered a solid performance in the fourth quarter, leading us to end 2025 00:00:58.277 -- 00:01:01.961 at the very top end of our latest outlook. 00:01:01.961 -- 00:01:07.448 So let me start out by highlighting three key strategic developments in the quarter. 00:01:07.448 -- 00:01:12.955 Firstly, the pediatric rollout of our house dust mite and tree pollen tablets, Acarisax 00:01:12.955 -- 00:01:14.977 and Etudasax, 00:01:14.977 -- 00:01:20.063 provides wider access to prescribers in key markets and continue to perform very 00:01:20.063 -- 00:01:25.687 well. Secondly, the European rollout of Euronefi, or just Nefi, 00:01:25.687 -- 00:01:29.353 continues following o...